Radio-attenuated leishmanial parasites as immunoprophylactic agent against experimental murine visceral leishmaniasis

Experimental Parasitology

Volumn 130, Issue 1, 2012, Pages 39-47

  Datta, Sanchita ^a   Adak, Rupchand ^a   Chakraborty, Priyanka ^a   Haldar, Arun Kumar ^b   Bhattacharjee, Surajit ^c   Chakraborty, Anindita ^d   Roy, Syamal ^b   Manna, Madhumita ^a  

^a BETHUNE COLLEGE   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^c BOSE INSTITUTE   (India)

^d UGC DAE CONSORTIUM FOR SCIENTIFIC RESEARCH   (India)

Author keywords

Immunization; Radio attenuated parasites; Th1 and Th2 cytokines; Visceral leishmaniasis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LEISHMANIA VACCINE; NITRITE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; GAMMA RADIATION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION RESISTANCE; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION ATTENUATION; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; CRICETINAE; CYTOKINES; FEMALE; GAMMA RAYS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MALE; MICE; MICE, INBRED BALB C; NITRITES; PROTOZOAN VACCINES; SPLEEN; SUPEROXIDES; VACCINES, ATTENUATED;

LEISHMANIA DONOVANI; MURINAE; MUS; NASO HEXACANTHUS;

EID: 84855955256     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.10.001     Document Type: Article

References (57)

1. Afrin J.F., Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infection and Immunity 1997, 65:2371-2377.
2. Alexander J. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana. Transactions of the Royal Society of Tropical Medicine and Hygiene 1982, 76:646-649.
3. Alexander J., Satoskar A.R., Russell D.G. Leishmania species: models of intracellular parasitism. Cell Science 1999, 112:2993-3002.
4. Ali N., Afrin J.F. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. Parasitology 1997, 83:70-75.
5. Alvar J., Canavate C., Gutierrez-Solar B., et al. Leishmania and human immunodeficiency virus infections: the first 10 years [review]. Clinical Microbiology Reviews 1997, 10:298-319.
6. Amato V., Amato J., Nicodemo A., Uip D., Amato-Neto V., Durate M. Treatment of mucocutaneous leishmaniasis with pentamidine isethionate. Annales de Dermatologie et de Venereologie 1990, 125:492-495.
7. Awasthi A., Mathur R.H., Saha B. Immune response to leishmania infection. Indian Journal of Medical Research 2004, 119:238-258.
8. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. Journal of Immunology 2005, 174:7160-7171.
9. Bhaumik S.K., Naskar K., De T. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donavani promastigotes involves Th-1 immunity and down regulation of IL-10. European Journal of Immunology 2009, 39:2146-2160.
10. Bhowmick S., Ravindran R., Ali N. Leishmania antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 2007, 25:6544-6556.
11. Bittencourt A., Barral-Netto M. Leishmaniasis. Tropical Pathology 1995, vol. 8:597-651. Springer, Heidelberg. second ed.
12. Bogdan C., Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. International Journal of Parasitology 1998, 28:121-134.
13. Connell N.D., Medina Acosta, McMaster E., et al. Effective immunization against cutaneous leishmaniasis with recombinant bacilli Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proceedings of the National Academy of Sciences of the United State of America 1993, 90:11473-11477.
14. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clinical Microbiology Reviews 2006, 19:111-126.
15. Datta, S., Naskar, K., Chakraborty, A., Manna, M., 2010. Immunotherapeutic role of radio attenuated Leishmania parasites in experimental murine leishmaniasis. In: Medimond International Proceedings (no.M815S7113). XIIth International Congress on Parasitology, August, Melbourne.
16. Desjeux P. Leishmaniasis: current situation and new perspectives. Comparative Immunology, Microbiology and Infectious Diseases 2004, 27:305-318.
17. Desjeux P., Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Annals of Tropical Medicine and Parasitology 2003, 97(Suppl.):3-15.
18. Engwerda C.R., Kaye P.M. Organ specific immune responses associated with infectious disease. Immunology Today 2000, 21:73-78.
19. Ferrua B., Luci C., Fichoux Y.L., Paul A., Marty P. Imprinting of BALB/c mice with low Leishmania infantum parasite dose markedly protects spleen against high-dose challenge. Vaccine 2006, 24(5):589-596.
20. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Analytical Biochemistry 1982, 126:131-138.
21. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nature Medicine 1998, 4:1409-1415.
22. Handman E. Leishmania vaccines: old and new. Parasitology Today 1997, 13:236-238.
23. Handman E., Button L.L., McMaster R.W. Leishmania major: production of recombinant gp63, its antigenecity and immunogenecity. Experimental Parasitology 1990, 70:427-435.
24. Howard J.G., Stephen N., Hale C., Liew F.Y. Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. Journal of Immunology 1982, 129:2206-2212.
25. Howard J.G., Liew F.Y., Hale C., Stephen N. Prophylactic immunization against experimental leishmaniasis. II. Further characterisation of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. Journal of Immunology 1984, 132:450-455.
26. Jackson J.E., Tally J.D., Ellis W.Y., Mebrahtu Y.B., Lawyer P.G., Were J.B., Reed J.G., Panisko D.M., Limmer B.L. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. American Journal of Tropical Medicine and Hygiene 1990, 43:464-480.
27. Kane M.M., Mosser D.M. The role of Il-10 promoting disease progression in leishmaniasis. Journal of Immunology 2001, 166:1141-1147.
28. Khamesipour A., Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 23:3642-3648.
29. Lemma A., Cole L. Leishmania enrrietti: radiation effects and evaluation of radioattenuated organisms for vaccination. Experimental Parasitology 1974, 35:161-169.
30. Liew F.Y., Hale C., Howard J.G. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. Journal of Immunology 1985, 135:2095-2101.
31. Manna M., Majumder H.K., Sundar S., Bhaduri A.N. Characterization of Indian Kala-azar clinical isolates by MLEE and RAPD-PCR. Medical Science Monitor 2005, 11:222-227.
32. Mathur R.K., Awasth I.A., Wadhone P., Ramanamurthy B., Saha B. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune response. Nature Medicine 2004, 10:540-544.
33. Mazumdar T., Anam K., Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 2004, 22:1162-1171.
34. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infection and Immunity 2001, 69:4719-4725.
35. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today 1996, 17:138-146.
36. Mukherjee P., Ghosh A.K., Ghose A.C. Infection pattern and immune response in the spleen and liver of BALB/c mice intracardially infected with Leishmania donovani amastigotes. Immunology Letters 2003, 86:131-138.
37. Mukhopadhyay S., Sen P., Bhattacharyya S., Majumder S., Roy S. Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis. Vaccine 1998, 17:291-300.
38. Mukhopadhyay S., Bhattacharyya S., Majhi R., De T., Naskar K., Majumder S., Roy S. Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis. Clinical and diagnostic laboratory Immunology 2000, 7:233-240.
39. Murphy M., Wille U., Villegas E.N., Hunter C.A., Farrell J.P. IL-10 mediates susceptibility to Leishmania donovani infection. European Journal of Immunology 2001, 31:2848-2856.
40. Murray H.W., Hariprashad J., Coffman R.L. Behavior of visceral Leishmania donovani in the experimentally induced T helper cell 2 (Th2)-associated response model. Journal of Experimental Medicine 1997, 185:867-874.
41. Murray H.W., Berman J.D., Davies C.R., Saravia N.G. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
42. Nylen S., Maasho K., Soderstrom K., Ilg T., Akuffo H. Live Leishmana promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clinical and Experimental Immunology 2003, 131:457-467.
43. Rachamim N., Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. Journal of Immunology 1993, 150:2322-2331.
44. Rivier D., Shah R., Bovay P., Mauel J. Vaccine development against cutaneous leishmaniasis: subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunology 1993, 15:75-84.
45. Rivier D., Bovay P., Shah R., Didisheim S., Mauel J. Vaccine against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunology 1999, 21:461-473.
46. Ronet C., Voigt H., Himmelrich H., Doucy M.A., Hauyon-La Torre Y., Revaz-Breton M., et al. Leishmania major specific B cells are necessary for Th2 cell development and susceptibility to L. major LV 39 in BALB/c mice. Journal of Immunology 2008, 180:4825-4835.
47. Rook G.A.W., Steele J., Umar S., Dockrell H.M. A simple method for solubilisation of reduced NBT and its use as a colorimetric assay for activation of human macrophages by g-interferon. Journal of Immunological Methods 1985, 82:161-167.
48. Rosa R., Marques C., Rodrigues O.R., Santos-Gomes G.M. Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th 1 specific immune response. Vaccine 2007, 25:4525-4532.
49. Selvapandiyan A., Duncan R., Debrabant A., Lee N., Sreenivas G., Salotra P., Nakhasi H.L. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian Journal of Medical Research 2006, 123:455-466.
50. Stager S., Smith D.F., Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. Journal of Immunology 2000, 165:7064-7071.
51. Stauber L.A. Host resistance to the Khartoum strain of Leishmania donovani. Rice Institute Pamphlet 1958, 45:80-96.
52. Strober W., 2001. Trypan blue exclusion test of cell viability. Current Protocol of Immunology. Appendix 3: Appendix 3B.
53. Sundar S. Drug resistances in Indian visceral leishmaniasis. Tropical Medicine and International Health 2001, 6:849-854.
54. Titus R.G., Guiros-Filho F.I., de Frietas L.A., Beverley S.A. Development of a safe, live leishmania vaccine by gene replacement. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:10267-10271.
55. Wanasen N., Xin L., Soong L. Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection. International Journal of Parasitology 2008, 38:417-429.
56. World Health Organization report on Leishmania and HIV in gridlock, 1998. WHO/UNAIDS report, Geneva, pp. 12-25.
57. Xu D., Liew F.Y. Genetic vaccination against leishmaniasis. Vaccine 1994, 12:1534-1536.